Sleep drug 'takes different approach to combating insomnia'

29 November 2012

A new drug offers a different approach to treating insomnia and could finally bring some rest to people with the condition, scientists have said.

The drug, called suvorexant, blocks chemical messengers in the brain known as orexins, which regulate wakefulness, according to a paper published in the journal Neurology.

Researchers found that the medication increased the amount of time that people spent asleep during the night.

Participants, who had insomnia that was not linked to another condition, took either the drug or the placebo for four weeks and then switched to the other treatment for a further four weeks, with the scientists monitoring their sleep efficiency.

The sleep efficiency regarded the total amount of time they spent during a fixed period of eight hours in bed, which improved by five to 13 per cent compared to those participants taking a placebo.

Study author W Joseph Herring commented: "This study provides evidence that suvorexant may offer a successful alternative strategy for treating insomnia.

"Suvorexant was generally well-tolerated, and there were no serious side effects."

Posted by Edward Bartel


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)